Status:
COMPLETED
Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This trial is conducted in Europe. The aim of this trial is to investigate the efficacy on blood glucose control in type 2 diabetes.
Eligibility Criteria
Inclusion
- Type 2 diabetes for at least 6 months
- Insulin naive. Short term insulin treatment (7 days or less within the last 6 months) is allowed
- Previous treatment with oral antidiabetic drugs for at least 4 months
- Judged by the investigator to be eligible for an insulin analogue plus oral antidiabetic drug treatment regimen
- BMI below 40 kg/m2
- HbA1c between 7-12%
- Able and willing to perform self-plasma glucose monitoring
Exclusion
- The receipt of any other investigational drug within 4 weeks before screening
- A history of drug or alcohol abuse within the last 12 months
- Severe, uncontrolled hypertension
- Known or suspected allergy to trial products or related products
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2005
Estimated Enrollment :
260 Patients enrolled
Trial Details
Trial ID
NCT00619697
Start Date
December 1 2003
End Date
March 1 2005
Last Update
January 6 2017
Active Locations (54)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Ebreichsdorf, Austria, 2483
2
Novo Nordisk Investigational Site
Feldkirch, Austria, 6807
3
Novo Nordisk Investigational Site
Graz, Austria, 8036
4
Novo Nordisk Investigational Site
Horn, Austria, A 3580